Related Experiment Videos
Hemodynamics and other determinants in development of left ventricular hypertrophy
Insights
Left ventricular hypertrophy in hypertension involves more than just increased afterload. Nonhemodynamic factors like hormones, age, and obesity also influence its development and regression with treatment.
Area of Science:
- Cardiology
- Hypertension Research
- Biomedical Science
Background:
- Left ventricular hypertrophy (LVH) in hypertension is traditionally linked to increased afterload.
- Emerging evidence highlights nonhemodynamic factors influencing LVH development and regression.
Purpose of the Study:
- To explore the role of nonhemodynamic factors in left ventricular hypertrophy.
- To discuss mechanisms behind LVH development and regression during antihypertensive therapy.
Main Methods:
- Review of existing literature on LVH in hypertension.
- Analysis of humoral, sexual, aging, racial, and comorbidity factors.
Main Results:
- Nonhemodynamic factors significantly contribute to LVH development and regression.
- Specific mechanisms linking these factors to biochemical events require further clarification.
Conclusions:
- Hypertension-induced LVH is multifactorial, involving hemodynamic and nonhemodynamic influences.
- Understanding these factors is crucial for targeted antihypertensive therapies and LVH regression.
Abstract:
Evidence is abundant supporting the premise that left ventricular hypertrophy in hypertension is related primarily to the hemodynamic factor of the increased left ventricular afterload associated with the disease. However, evidence is rapidly accumulating that additional, nonhemodynamic factors are associated not only with development of left ventricular hypertrophy but also with its regression that is related to antihypertensive therapy. Included among these mechanisms are humoral factors, including a variety of participating (or inhibited) circulating pressor mechanisms (e.g., angiotensin, catecholamines); sexual factors; aging; racial factors; and the role of obesity and coexisting diseases. Precisely how each factor is translated into the biochemical events associated with development of hypertrophy remains to be clarified, as do the explanatory mechanisms of why certain depressor agents produce regression of ventricular hypertrophy, whereas other agents with more salutary hemodynamic effects do not. This paper discusses the rationale and evidence underlying each of these factors.